- Conditions: Obesity; Overweight
Interventions: Drug: NB32; Drug: PBO; Behavioral: Weight Management Program
Sponsors: Orexigen Therapeutics, Inc; Orexigen Therapeutics, Inc
Not yet recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Glycemic Control
Interventions: Drug: TAK-875; Drug: Sitagliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified May 2012 - Conditions: Hypertension; Diabetes
Interventions: Drug: Placebo; Drug: Azilsartan medoxomil; Drug: Azilsartan medoxomil
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - New formulation of insulin glargine; Drug: HOE 901 - Insulin glargine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: DS-5565 tablet; Drug: pregabalin capsule; Drug: Placebo
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012 - Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Disease
Interventions: Drug: CTP-499; Drug: Placebo
Sponsors: Concert Pharmaceuticals; Concert Pharmaceuticals
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Atorvastatin; Other: Placebo to sitagliptin; Other: Placebo to atorvastatin; Drug: Metformin; Drug: Glimepiride; Drug: Placebo to glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: TAK-875; Drug: TAK-875
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Diabetes Mellitus
Intervention: Drug: AMG 151
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Conditions: Gastroparesis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 10mg TZP-102; Drug: 20mg TZP-102
Sponsors: Tranzyme, Inc.; Tranzyme, Inc.
Recruiting - verified April 2012 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Technosphere Insulin with MedToneC Inhaler in combination with a basal insulin; Drug: Technosphere Insulin with Gen2C Inhaler in combination with a basal insulin; Drug: Insulin Aspart in combination with a basal insulin
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Conditions: Choroidal Neovascularization; Diabetic Retinopathy; Diabetic Macular Edema
Interventions: Drug: PF-04523655 (Stratum I); Drug: PF-04523655 and ranibizumab; Drug: ranibizumab; Drug: PF-04523655 (Stratum II)
Sponsors: Quark Pharmaceuticals; Quark Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diabetes Mellitus Type II
Intervention:
Sponsors: Fairbanks Institute; Fairbanks Institute; Indiana University School of Medicine; Richard M. Fairbanks Foundation; BioCrossroads; Regenstrief Institute, IU Center for Aging Research
Recruiting - verified June 2011 - Conditions: Primary Prevention; Diabetes Mellitus; Asthma; Cardiovascular Diseases; Heart Failure; Mental Health; Osteoporosis
Intervention:
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Regenstrief Institute, IU Center for Aging Research
Not yet recruiting - verified March 2012 - Conditions: Diabetes; Diabetic Retinopathy
Intervention: Behavioral: Diabetes Education
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Gestational Diabetes Mellitus
Interventions: Drug: Glyburide; Drug: Metformin; Drug: Glyburide-Metformin combination
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Washington; University of Pittsburgh; University of Texas; Indiana University School of Medicine; RTI International
Recruiting - verified January 2012 - Conditions: Fibromyalgia; Painful Diabetic Peripheral Neuropathy
Interventions: Other: prior authorization; Other: no prior authorization; Other: prior authorization; Other: no prior authorization
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: liraglutide; Drug: insulin detemir; Drug: liraglutide plus insulin detemir
Sponsors: Indiana University; Indiana University; Novo Nordisk
Recruiting - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin lispro; Drug: Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Pioglitazone 15 mg; Drug: Pioglitazone 45 mg; Drug: Pioglitazone 30 mg; Drug: BI 1356 / Pioglitazone 15 mg FDC; Drug: BI 1356; Drug: BI 1356 / Pioglitazone 30 mg FDC; Drug: BI 1356 / Pioglitazone 45 mg FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk; Impaired Glucose Tolerance
Intervention: Drug: Teplizumab
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified February 2012 - Conditions: Vitreous Hemorrhage; Proliferative Diabetic Retinopathy
Interventions: Drug: Ranibizumab; Behavioral: Saline
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI)
Recruiting - verified February 2012 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Conditions: Obesity, Morbid; Diabetes Mellitus Type 2
Intervention:
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified January 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2011 - Condition: Type 2 Diabetes
Interventions: Drug: placebo; Drug: exenatide; Drug: exenatide
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified August 2011 - Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011
 |
Join Clinical Trials in Indiana for Diabetes |
